



*ZPW*  
*GPA/1713*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of ) Confirmation No.: 6064  
 )  
SCHADE et al. ) Art Unit: 1713  
 )  
Serial No. 08/325,219 ) Examiner: ZALUKAEVA  
 )  
Filing or 371(c) Date: October 21, 1994 )

For: THE USE OF COPOLYMERS OF CARBOXYLIC ACIDS AND LONG CHAIN  
COMPOUNDS WITH ISOLATED C-C MULTIPLE BONDS AS THICKENERS OR  
DISPERSANTS

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on April 22, 2005.

Typed or printed name of person signing this certificate: Sabine Berg

Signature: *S. Berg*

Honorable Commissioner for Patents  
Alexandria, Virginia 22313-1450

STATUS INQUIRY


Applicants request a status report on the above-identified application. Applicants filed a Petition to Withdraw the Holding of Abandonment on June 18, 2002 (copy enclosed with postcard receipt). Applicants continue to await a response thereto.

Please charge any shortage in fees due in connection with the filing of this paper to Deposit Account No. 14.1437. Please credit any excess fees to such account.

Respectfully submitted,  
NOVAK DRUCE DeLUCA & QUIGG LLP

*J. D. Voight*  
Jason D. Voight  
Reg. No. 42,205

Customer No. 26474  
1300 Eye Street, N.W.  
Suite 400 East  
Washington, D.C. 20005  
(202) 659-0100



June 12, 2002

SCHADE et al.  
S.N. 325,219

Received: petition to withdraw abandonment  
copy of continuation transmittal  
copy of preliminary submission



BEST AVAILABLE COPY



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION

OF: SCHADE ET AL.

CONFIRMATION No.: 6064

SERIAL No. 08/325,219

GROUP ART UNIT: 1713

FILED: OCTOBER 21, 1994

EXAMINER:

FOR: THE USE OF COPOLYMERS OF CARBOXYLIC ACIDS AND LONG CHAIN COMPOUNDS WITH ISOLATED C-C MULTIPLE BONDS AS THICKENERS OR DISPERSANTS

TATYANA ZALUKAEVA

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner of Patents and Trademarks, Washington, D.C. 20231, on:

June 12, 2002

Date of Deposit

Herbert B. Keil

Person Making Deposit

Signature

June 12, 2002

Date of Signature

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

PETITION UNDER 37 C.F.R. §1.181  
TO WITHDRAW THE HOLDING OF ABANDONMENT

Sir:

Applicants hereby petition to the Honorable Commissioner to withdraw the holding of abandonment indicated in the Notification dated May 31, 2002 (*marked as Paper No. 23*).

STATEMENT OF MATERIAL FACTS:

1. On March 20, 2002 (*indicated date of Mailing*), the Board of Patent Appeals and Interferences issued a decision sustaining the appealed rejection.
2. On May 20, 2002, applicants filed a continuation application under 37 C.F.R. §1.53(d) (*copy of Form PTO/SB/29 enclosed*), along with a preliminary submission including a preliminary amendment of the claims (*marked as Paper No. 23; copy enclosed*).
3. In a Notification dated May 31, 2002, the Examiner indicated that the application is abandoned because the period for seeking court review of the Board's decision had expired and because there were no allowed claims.

M E M O R A N D U M

37 C.F.R. §1.53(d) provides that a continuation application may be filed before termination of proceedings on a prior application, "before" meaning in this context "*not later than*" (ie. MPEP §711.02(c)).

In light of the Boards decision of March 20, 2002, the proceedings in the prior application were terminated on the date on which the time for an appeal to the court or review by civil action expired, ie. May 20, 2002, (ie. 37 C.F.R. §1.197(c) and §1.304). Accordingly, applicants' continuation application was timely submitted. A holding that application Serial No. 08/325,219 was abandoned is, therefore, not deemed appropriate.

C O N C L U S I O N

Applicants therefore respectfully request that the holding of abandonment dated May 31, 2002, be withdrawn and that the application be returned to the Examiner for entry and full consideration of applicants' continuation application. Favorable action is respectfully solicited.

Please charge any shortage in fees due in connection with the filing of this paper, including Extension of Time fees to Deposit Account No. 11.0345. Please credit any excess fees to such deposit account.

Respectfully submitted,

KEIL & WEINKAUF




Herbert B. Keil

Reg. No. 18,967

1350 Connecticut Ave, N.W.  
Washington, D.C. 20036  
(202) 659-0100

Encl.: copy of Form PTO/SB/29  
copy of CPA Preliminary Submission/Amendment

HBK/BAS



## CONTINUED PROSECUTION APPLICATION (CPA)

### REQUEST TRANSMITTAL

Submit an original, and a duplicate for fee processing.  
 Only for Continuation or Divisional applications under 37 CFR 1.53(d))

CHECK BOX, if applicable:  
☐ DUPLICATE

Address to: <div style="text-align: center; margin-top: 10px;"> <b>Assistant Commissioner for Patents</b>  <b>Box CPA</b>  <b>Washington, DC 20231</b> </div>	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="padding: 2px;">Attorney Docket No. <small>of Prior Application</small></td> <td style="padding: 2px;">0050/43168</td> </tr> <tr> <td style="padding: 2px;">First Named Inventor</td> <td style="padding: 2px;">SCHADE et al.</td> </tr> <tr> <td style="padding: 2px;">Examiner Name</td> <td style="padding: 2px;">Wu</td> </tr> <tr> <td style="padding: 2px;">Group Art Unit</td> <td style="padding: 2px;">1713</td> </tr> <tr> <td style="padding: 2px;">Express Mail Label No.</td> <td style="padding: 2px;"></td> </tr> </table>	Attorney Docket No. <small>of Prior Application</small>	0050/43168	First Named Inventor	SCHADE et al.	Examiner Name	Wu	Group Art Unit	1713	Express Mail Label No.	
Attorney Docket No. <small>of Prior Application</small>	0050/43168										
First Named Inventor	SCHADE et al.										
Examiner Name	Wu										
Group Art Unit	1713										
Express Mail Label No.											

This is a request for a ☒ continuation or ☐ divisional application under 37 CFR 1.53(d),  
 (continued prosecution application (CPA)) of prior application number 08 / 325,219,  
 filed on 10/21/94, entitled USE OF COPOLYMERS OF CARBOXYLIC ACIDS AND LONG CHAIN...

**NOTES**

**FILING QUALIFICATIONS:** The prior application identified above must be a nonprovisional application that is either: (1) complete as defined by 37 CFR 1.51(b), or (2) the national stage of an international application in compliance with 35 U.S.C. 371. Effective May 29, 2000, a CPA may only be filed in a utility or a plant application if the prior nonprovisional application was filed before May 29, 2000. A CPA may be filed in a design application regardless of the filing date of the prior application. See "Request for Continued Examination Practice changes to and Provisional Application Practice," Final Rule, 65 Fed. Reg. 50092 (Aug. 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office (Apr. 11, 2000).

**C-I-P NOT PERMITTED:** A continuation-in-part application cannot be filed as a CPA under 37 CFR 1.53(d), but must be filed under 37 CFR 1.53(b).

**EXPRESS ABANDONMENT OF PRIOR APPLICATION:** The filing of this CPA is a request to expressly abandon the prior application as of the filing date of the request for a CPA. 37 CFR 1.53(b) must be used to file a continuation, divisional, or continuation-in-part of an application that is not to be abandoned.

**ACCESS TO PRIOR APPLICATION:** The filing of this CPA will be construed to include a waiver of confidentiality by the applicant under 35 U.S.C. 122 to the extent that any member of the public who is entitled under the provisions of 37 CFR 1.14 to access to, copies of, or information concerning, the prior application may be given similar access to, copies of, or similar information concerning, the other application or applications in the file jacket.

**35 U.S.C. 120 STATEMENT:** In a CPA, no reference to the prior application is needed in the first sentence of the specification and none should be submitted. If a sentence referencing the prior application is submitted, it will not be entered. A request for a CPA is the specific reference required by 35 U.S.C. 120 and to every application assigned the application number identified in such request, 37 CFR 1.78(a).

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

1. ☐ Enter the unentered amendment previously filed on \_\_\_\_\_  
 under 37 CFR 1.116 in the prior nonprovisional application.
2. ☒ A preliminary amendment is enclosed.
3. This application is filed by fewer than all the inventors named in the prior application, 37 CFR 1.53(d)(4).
  - a. ☐ **DELETE** the following inventor(s) named in the prior nonprovisional application:  
 \_\_\_\_\_
  - b. ☐ The inventor(s) to be deleted are set forth on a separate sheet attached hereto.
4. ☐ A new power of attorney or authorization of agent (PTO/SB/81) is enclosed.
5. Information Disclosure Statement (IDS) is enclosed:
  - a. ☐ PTO-1449
  - b. ☐ Copies of IDS Citations

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

CLAIMS	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16(c) or (j))	7 -20* =		x \$ _____ =	\$
	INDEPENDENT CLAIMS (37 CFR 1.16(b) or (i))	2 -3** =		x \$ _____ =	
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR 1.16(d))			+ \$ _____ =	
				BASIC FEE (37 CFR 1.16)	740.00
				Total of above Calculations =	
	Reduction by 50% for filing by small entity (Note 37 CFR 1.27).				
	* Reissue claims in excess of 20 and over original patent. ** Reissue independent claims over original patent.				
				TOTAL =	740.00

6. ☐ Small entity status: Applicant claims small entity status. See 37 CFR 1.27.7. The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. 11 - 0345 ANY DEFICIENCY IN FEESa. ☐ Fees required under 37 CFR 1.16.b. ☐ Fees required under 37 CFR 1.17.c. ☐ Fees required under 37 CFR 1.18.8. ☒ A check in the amount of \$ 740.00 is enclosed.9. ☐ Payment by credit card. Form PTO-2038 is attached.10. ☐ Applicant requests suspension of action under 37 CFR 1.103(b) for a period of \_\_\_\_\_ months (not to exceed 3 months) and the fee under 37 CFR 1.17(i) is enclosed.11. ☐ New Attorney Docket Number, if desired \_\_\_\_\_*[Prior application Attorney Docket Number will carryover to this CPA unless a new Attorney Docket Number has been provided herein.]*12. a. ☐ Receipt For Facsimile Transmitted CPA (PTO/SB/29A)b. ☒ Return Receipt Postcard (Should be specifically itemized, See MPEP 503)13. ☐ Other: \_\_\_\_\_**NOTE:***The prior application's correspondence address will carry over to this CPA UNLESS a new correspondence address is provided below.***14. NEW CORRESPONDENCE ADDRESS**☐ Customer Number or Bar Code Label

26474

(Insert Customer No. or Attach bar code label here)

or ☐ New correspondence address below

Name

**KEIL & WEINKAUF**

Address

**1350 Connecticut Avenue, N.W.  
Washington, D.C. 20036**

City

State

Zip Code

Country

USA

Telephone

(202) 659-0100

Fax

(202) 659-0105

**15. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED**

Name (Print /Type)

Herbert B. Keil

Signature

18,967

Registration No. (Attorney/Agent)

Date

May 20, 2002



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE C. P. APPLICATION

Box: CPA

OF: SCHADE ET AL.

CONFIRMATION No.: -/-

SERIAL No. 08/325,219

GROUP ART UNIT: 1713

FILED: OCTOBER 21, 1994

EXAMINER: DAVID W. WU

FOR: THE USE OF COPOLYMERS OF CARBOXYLIC ACIDS AND LONG  
CHAIN COMPOUNDS WITH ISOLATED C-C MULTIPLE BONDS AS  
THICKENERS OR DISPERSANTS

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

CONTINUED PROSECUTION APPLICATION

PRELIMINARY SUBMISSION

Sir:

This is a Continued Prosecution application pursuant to 37 C.F.R. §1.53(d), of application Serial No. 08/325,219, filed on October 21, 1994, which is filed in reply to the Decision of the Board of Patent Appeals and Interferences dated March 20, 2002. For further prosecution, kindly enter and consider the following preliminary amendment and remarks:

PRELIMINARY AMENDMENT

IN THE SPECIFICATION:

Amend the specification as set forth in Appendix I attached to this paper. A marked up version indicating the changes made in the respective paragraphs of the specification is found in Appendix II.

IN THE CLAIMS:

Amend the claims as indicated in Appendix III attached to this paper. A clean copy of the claims as herewith amended is found in the attached Appendix IV.

PRELIMINARY REMARKS

Claims 10 to 15 and 17 as set forth in Appendix IV of this paper are now pending in this case. Claims 10, 13, 15 and 17 have been amended as indicated in Appendix III of this paper. The specification has been amended to set forth the continuing data of the application (ie. *Appendix I and Appendix II of this paper*). No new matter has been added.

Applicants have amended Claims 10, 13, 15 and 17 to further specify the nature of the long-chain compounds which constitute component (B) of the copolymer utilized in applicants' composition as a thickener or dispersant. Accordingly, the constituent (B) of the copolymer is now specified as one or more compounds selected from the groups of

(1) mono- or polyunsaturated C<sub>8</sub>-C<sub>30</sub>-monocarboxylic acids which may have additional hydroxyl groups, as well as their alkali metal and alkaline earth metal salts, alkyl esters, amides, sorbitan esters, glycerol esters or polyglycerol esters,

(2) mono- or polyunsaturated aliphatic C<sub>8</sub>-C<sub>30</sub>-amines, and

(3) mono- or polyunsaturated C<sub>8</sub>-C<sub>30</sub>-alcohols as well as their esters with saturated C<sub>1</sub>-C<sub>4</sub>-monocarboxylic acids,

(ie. *Claim 10*). In light of the respective amendment, the copolymers of applicants' invention no longer fall within the generic realm of the copolymers taught by **George** (EP 047 009) which require a combination of

- from 65 to 90% by weight of acrylic acid monomers, and
- from 10 to 35% by weight of an  $\alpha$ -olefin having 6 to 18 carbon atoms, styrene or a substituted styrene,

(ie. *page 2, indicated lines 19 to 26, of EP 047 009*). The disclosure of **George** provides nothing which would suggest or imply the modifications of the copolymers which are necessary to arrive at the copolymer of applicants' invention. The referenced prior art teaching therefore fails to render the subject matter of applicants' claims *prima facie* obvious. Favorable action is respectfully solicited.

Please charge any shortage in fees due in connection with the filing of this paper, including Extension of Time fees to Deposit



Serial No. 08/325,219

SCHADE et al.

OZ 0050/43168

Account No. 11.0345. Please credit any excess fees to such deposit account.

Respectfully submitted,

KEIL & WEINKAUF



Herbert B. Keil

Reg. No. 18,967

1350 Connecticut Ave, N.W.  
Washington, D.C. 20036  
(202) 659-0100

Encl.: THE SUBSTITUTE SECTION(S) OF THE SPECIFICATION (Appendix I)  
THE CHANGE(S) IN THE SPECIFICATION (Appendix II)  
THE CHANGES IN THE CLAIMS (Appendix III)  
THE AMENDED CLAIMS (Appendix IV)

HBK/BAS

A P P E N D I X I:

THE SUBSTITUTE SECTION(S) OF THE SPECIFICATION:

On page 1:

- After the title and prior to the first paragraph, ie. at indicated line 5, insert the following:

CROSS-REFERENCE TO RELATED APPLICATIONS

This is a Continued Prosecution Application of U.S. Application Serial No. 08/325,219, which was filed on October 21, 1994.

A P P E N D I X II:

THE CHANGE(S) IN THE SPECIFICATION:

On page 1:

- After the title and prior to the first paragraph, ie. at indicated line 5, the following new paragraph has been added:

CROSS-REFERENCE TO RELATED APPLICATIONS

This is a Continued Prosecution Application of U.S. Application Serial No. 08/325,219, which was filed on October 21, 1994.

## A P P E N D I X III:

THE CHANGES IN THE CLAIMS:

Amend Claim 10 as indicated in the following:

10. (trice amended) A cosmetic or pharmaceutical composition, containing as a thickener or dispersant an effective amount of a copolymer obtained by free radical polymerization of
- A) 50 - 99.9% by weight of an olefinically unsaturated C<sub>3</sub>-C<sub>5</sub>-monocarboxylic acid, of an olefinically unsaturated C<sub>4</sub>-C<sub>8</sub>-dicarboxylic acid or of its anhydride or a mixture of such carboxylic acids or anhydrides with
  - B) 0.1 - 50% by weight of one or more long-chain compounds with isolated C-C multiple bonds selected from the group consisting of
    - (1) mono- or polyunsaturated C<sub>8</sub>-C<sub>30</sub>-monocarboxylic acids which may have additional hydroxyl groups, as well as their alkali metal and alkaline earth metal salts, alkyl esters, amides, sorbitan esters, glycerol esters or polyglycerol esters,
    - (2) mono- or polyunsaturated aliphatic C<sub>8</sub>-C<sub>30</sub>-amines, and
    - (3) mono- or polyunsaturated C<sub>8</sub>-C<sub>30</sub>-alcohols as well as their esters with saturated C<sub>1</sub>-C<sub>4</sub>-monocarboxylic acids,
    - ~~[(4) C<sub>10</sub>-C<sub>25</sub>-alkyl vinyl ethers, and]~~
    - ~~[(5) terminal or internal C<sub>16</sub>-C<sub>30</sub>-alkenes,]~~
  - C) 0 - 49.9% by weight of other copolymerizable monomers and
  - D) 0 - 10% by weight of one or more compounds with at least two olefinically unsaturated groups in the molecule as crosslinkers.

Amend Claim 13 as indicated in the following:

13. (twice amended) A composition as defined in claim 10, wherein the copolymers have been prepared using as component B one or more long-chain compounds with isolated double bonds selected from the group consisting of
- (1) mono- to tetraunsaturated C<sub>14</sub>-C<sub>24</sub>-monocarboxylic acids, as well as their alkali metal and alkaline earth metal salts, C<sub>1</sub>-C<sub>4</sub>-alkyl esters, glycerol esters or polyglycerol esters,

- (2) mono- to tetraunsaturated aliphatic primary C<sub>14</sub>-C<sub>24</sub>-amines, and
- (3) mono- to tetraunsaturated primary C<sub>14</sub>-C<sub>24</sub>-alcohols as well as their esters with saturated C<sub>1</sub>-C<sub>4</sub>-monocarboxylic acids. [7]
- ~~[(4) C<sub>10</sub>-C<sub>23</sub>-alkyl vinyl ethers, and]~~
- ~~[(5) terminal C<sub>16</sub>-C<sub>24</sub>-alkenes.]~~

Amend Claim 15 as indicated in the following:

15. (trice amended) A copolymer obtained by free-radical polymerization of
- A) 50 - 99.9% by weight of an olefinically unsaturated C<sub>3</sub>-C<sub>5</sub>-monocarboxylic acid, of an olefinically unsaturated C<sub>4</sub>-C<sub>8</sub>-dicarboxylic acid or of its anhydride or a mixture of such carboxylic acids or anhydrides with
  - B) 0.1 - 50% by weight of one or more long-chain compounds with isolated C-C multiple bonds selected from the group consisting of
    - (1) mono- to tetraunsaturated C<sub>14</sub>-C<sub>30</sub>-monocarboxylic acids as well as their alkali metal and alkaline earth metal salts, C<sub>1</sub>-C<sub>4</sub>-alkyl esters, glycerol esters or polyglycerol esters,
    - (2) mono- or polyunsaturated aliphatic C<sub>8</sub>-C<sub>30</sub>-amines, and
    - (3) mono- or polyunsaturated C<sub>8</sub>-C<sub>30</sub>-alcohols as well as their esters with saturated C<sub>1</sub>-C<sub>4</sub>-monocarboxylic acids,
    - ~~[(4) C<sub>10</sub>-C<sub>23</sub>-alkyl vinyl ethers.]~~
  - C) 0 - 49.9% by weight of other copolymerizable monomers and
  - D) 0 - 10% by weight of one or more compounds with at least two olefinically unsaturated groups in the molecule as crosslinkers.

Amend Claim 17 as indicated in the following:

17. (amended) A cosmetic or pharmaceutical composition as defined in claim 10 and containing as a thickener or dispersant an effective amount of a copolymer obtained by free radical polymerization of
- A) 50 - 99.9% by weight of an olefinically unsaturated C<sub>3</sub>-C<sub>5</sub>-monocarboxylic acid;
  - B) 0.1 - 50% by weight of one or more long-chain compounds with isolated C-C multiple bonds from the group comprising

- (1) mono- or polyunsaturated C<sub>8</sub>-C<sub>30</sub>-monocarboxylic acids,
  - (2) mono- or polyunsaturated aliphatic C<sub>8</sub>-C<sub>30</sub>-amines, and
  - (3) mono- or polyunsaturated C<sub>8</sub>-C<sub>30</sub>-alcohols,
  - ~~[(4) C<sub>10</sub>-C<sub>25</sub> alkyl vinyl ethers, and]~~
  - ~~[(5) terminal or internal C<sub>16</sub>-C<sub>30</sub> alkenes,]~~
- C) 0 - 49.9% by weight of other copolymerizable monomers, and
- D) 0 - 10% by weight of one or more compounds with at least two olefinically unsaturated groups in the molecule as crosslinkers.

## A P P E N D I X IV:

THE AMENDED CLAIMS:

10. (*trice amended*) A cosmetic or pharmaceutical composition, containing as a thickener or dispersant an effective amount of a copolymer obtained by free radical polymerization of
- A) 50 - 99.9% by weight of an olefinically unsaturated C<sub>3</sub>-C<sub>5</sub>-monocarboxylic acid, of an olefinically unsaturated C<sub>4</sub>-C<sub>8</sub>-dicarboxylic acid or of its anhydride or a mixture of such carboxylic acids or anhydrides with
  - B) 0.1 - 50% by weight of one or more long-chain compounds with isolated C-C multiple bonds selected from the group consisting of
    - (1) mono- or polyunsaturated C<sub>8</sub>-C<sub>30</sub>-monocarboxylic acids which may have additional hydroxyl groups, as well as their alkali metal and alkaline earth metal salts, alkyl esters, amides, sorbitan esters, glycerol esters or polyglycerol esters,
    - (2) mono- or polyunsaturated aliphatic C<sub>8</sub>-C<sub>30</sub>-amines, and
    - (3) mono- or polyunsaturated C<sub>8</sub>-C<sub>30</sub>-alcohols as well as their esters with saturated C<sub>1</sub>-C<sub>4</sub>-monocarboxylic acids,
  - C) 0 - 49.9% by weight of other copolymerizable monomers and
  - D) 0 - 10% by weight of one or more compounds with at least two olefinically unsaturated groups in the molecule as crosslinkers.
11. (*amended*) A composition as defined in claim 10, wherein the copolymers are obtained by free-radical polymerization of
- A) 75 - 99.45% by weight of carboxylic acid component A,
  - B) 0.5 - 24.95% by weight of the long-chain compounds with isolated C-C multiple bonds B,
  - C) 0 - 24.45% by weight of other copolymerizable monomers and
  - D) 0.05 - 5% by weight of crosslinker component D.
12. (*amended*) A composition as defined in claim 10, wherein the copolymers have been prepared using acrylic acid, methacrylic acid or maleic anhydride as component A.
13. (*twice amended*) A composition as defined in claim 10, wherein the copolymers have been prepared using as component B one or more

long-chain compounds with isolated double bonds selected from the group consisting of

- (1) mono- to tetraunsaturated C<sub>14</sub>-C<sub>24</sub>-monocarboxylic acids, as well as their alkali metal and alkaline earth metal salts, C<sub>1</sub>-C<sub>4</sub>-alkyl esters, glycerol esters or polyglycerol esters,
  - (2) mono- to tetraunsaturated aliphatic primary C<sub>14</sub>-C<sub>24</sub>-amines, and
  - (3) mono- to tetraunsaturated primary C<sub>14</sub>-C<sub>24</sub>-alcohols as well as their esters with saturated C<sub>1</sub>-C<sub>4</sub>-monocarboxylic acids.
14. (*amended*) A composition as defined in claim 10, wherein the copolymers are used which have been prepared using as component D allyl ethers of pentaerythriol, trimethylolpropane or sucrose with at least two allyl ether units in the molecule as well as allylether methacrylate, oleyl (meth)acrylate or methylenebisacrylamide.
15. (*trice amended*) A copolymer obtained by free-radical polymerization of
- A) 50 - 99.9% by weight of an olefinically unsaturated C<sub>3</sub>-C<sub>5</sub>-monocarboxylic acid, of an olefinically unsaturated C<sub>4</sub>-C<sub>8</sub>-dicarboxylic acid or of its anhydride or a mixture of such carboxylic acids or anhydrides with
  - B) 0.1 - 50% by weight of one or more long-chain compounds with isolated C-C multiple bonds selected from the group consisting of
    - (1) mono- to tetraunsaturated C<sub>14</sub>-C<sub>30</sub>-monocarboxylic acids as well as their alkali metal and alkaline earth metal salts, C<sub>1</sub>-C<sub>4</sub>-alkyl esters, glycerol esters or polyglycerol esters,
    - (2) mono- or polyunsaturated aliphatic C<sub>8</sub>-C<sub>30</sub>-amines, and
    - (3) mono- or polyunsaturated C<sub>8</sub>-C<sub>30</sub>-alcohols as well as their esters with saturated C<sub>1</sub>-C<sub>4</sub>-monocarboxylic acids,
  - C) 0 - 49.9% by weight of other copolymerizable monomers and
  - D) 0 - 10% by weight of one or more compounds with at least two olefinically unsaturated groups in the molecule as crosslinkers.
17. (*amended*) A cosmetic or pharmaceutical composition as defined in claim 10 and containing as a thickener or dispersant an effective amount of a copolymer obtained by free radical polymerization of



- A) 50 - 99.9% by weight of an olefinically unsaturated C<sub>3</sub>-C<sub>5</sub>-monocarboxylic acid;
- B) 0.1 - 50% by weight of one or more long-chain compounds with isolated C-C multiple bonds from the group comprising
  - (1) mono- or polyunsaturated C<sub>8</sub>-C<sub>30</sub>-monocarboxylic acids,
  - (2) mono- or polyunsaturated aliphatic C<sub>8</sub>-C<sub>30</sub>-amines, and
  - (3) mono- or polyunsaturated C<sub>8</sub>-C<sub>30</sub>-alcohols,
- C) 0 - 49.9% by weight of other copolymerizable monomers, and
- D) 0 - 10% by weight of one or more compounds with at least two olefinically unsaturated groups in the molecule as crosslinkers.